fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Inflationary Fears Flamed Markets Decline Until Fed’s ‘Transitory’ Statement Entered Investors’ Minds

By John F. Heerdink, Jr.
Inflationary Fears Flamed Markets


“Cash – in savings accounts, short-term CDs or money market deposits – is great for an emergency fund. But to fulfill a long-term investment goal like funding your retirement, consider buying stocks. The more distant your financial target, the longer inflation will gnaw at the purchasing power of your money.”  – Suze Orman


Happy Saturday All!

I hope that all of you had a great week and once again made progress towards creating generational wealth for you and your family.

However, this week, investors found things in general to be a bit more challenging and I would suggest a sort of a ‘beat down’ in the markets as it legged down for the majority of the week. Especially within the growth sectors of tech and biotech, until we saw a significant swing during Friday’s session. For the week, 8 of the 11 sectors ended in the red & 3 sectors led the decline as follows:  the consumer discretionary sector lost 3.7%, the information technology sector lost 2.2%, & the communication services sector fell 2%.

The market’s sell off, after last week’s record results, were primarily fed by the poisonous and unfounded belief and subsequent fear that inflation is getting out of control and the Fed would need to raise rates to curb it. On Wednesday, the CPI numbers came in above expectations and further flamed the fires of this belief. However, on Thursday the Fed’s Waller reconfirmed that inflation pressures are likely ‘transitory’ and urged patience, which is not something many folks have these days. Nevertheless, investors surprisingly seemed to grasp the concept that we experiencing a temporary rise in prices that is powered by a temporary disruption of supply across many sectors caused by the closure or reduction in production during the COVID pandemic shutdown. This is coupled with the fact that we are getting back to work and life, along with a flood of money from Uncle Sam’s stimulus packages. This situation is breeding the increased willingness to purchase & speculate and further exacerbating the temporary surge of some prices that should be remedied over the next few months as supply issues normalize once again. For an example, check out what is going in the automobile industry by going to buy a car or rent a car and you will see this that temporary situation is evident. 

The CDC also did their part on Thursday to calm investors nerves, indirectly that is, by specifically stating that if you are fully vaccinated, you can resume activities that you did prior to the pandemic. Fully vaccinated people can resume activities without wearing a mask or physically distancing, except where required by federal, state, local, tribal, or territorial laws, rules, and regulations, including local business and workplace guidance. They also stated that if you haven’t been vaccinated yet, then find a vaccine today. This is the first move that the CDC has made recently that I completely agreed with and seemed to clear the air the nation.

At the end of the week, the major indices performed as follows:  The Dow 30 closed at 34,382.13 (-1.1%) for the week & remains up +12.3% YTD & the S&P 500 closed at 4,173.85 (-1.4%) for the week and remains up +11.1% YTD. The Nasdaq closed at 13,429.98 (-2.3%) for the week and remains up +4.2% YTD. The smalls on the Russell 2000 closed at 2,271.63 (-2.1%) for the week & remains up +12.6% YTD.  

The FAANGs ended lower as follows: Apple (AAPL) shares closed at $127.45 down $2.76 from last Friday’s close of $130.21, Amazon (AMZN) closed at $3,222.90 down $68.71 from last Friday’s close of $3,291.61, Alphabet (GOOG) closed at $2,316.16 down $82.53/share from last Friday’s close of $2,398.69, Facebook (FB) closed at $315.94 down $3.14/share from last Friday’s close of $319.08 & Netflix (NFLX) closed at $493.37 down $10.47/share down from last Friday’s close of $503.84/share.  

Leading EV car maker Tesla (TSLA) moved lower again this week to close at $589.74 & down $82.63/share from the $672.37 close. This also came after Elon Musk further upset the croton markets this week by stating that Tesla would not be accepting Bitcoin for payment as it comes with “a high environmental cost with a rapidly increasing use of fossil fuels, especially coal, which has the worst emissions of any fuel.”

THE MACRO & RATES 

On Tuesday, the job openings report confirmed a rise to 8.123M in March & the NFIB Small Business Optimism Index report for April also confirmed a rise to 99.8.  On Wednesday, the CPI report surfaced confirming an .8% m/m rise in April. The Treasury Budget report for April confirmed a $225.6B deficit & the weekly MBA Mortgage Applications report showed a 2.1% rise. On Thursday, the PPI for final demand report confirmed a rise by .6% m/m. The index for final demand rose .7% m/m. For the week ending May 8 the initial jobless claims report confirmed a drop by 34k to 473k, while continuing claims for the week ending May 1 dropped by 45k to 3.655M. On Friday, the total retail sales report confirmed a flat m/m performance in April. The preliminary May reading for the University of Michigan Index of Consumer Sentiment fell to 82.8. The total industrial production report confirmed a rise by .7% month/month in April, while the capacity utilization rate rose to 74.9%. Import prices moved higher by .7% m/m in April , while export prices rose .8% m/m in April.  Business inventories also rose .3% month/month in March. Next week, we will receive the existing home sales report and the PMI index report.

The yield curve was relatively calm this week as the 10-yr yield rose 6 basis points wk/wk to close 1.64, while the 2-yr settled flat wk/wk at .14%. The U.S. Dollar Index ticked higher from 90.22 to 90.32. 


VISTA STORIES FROM THE DOW 30

Chevron & Noble Midstream Partners LP Announce Complete Merger

IBM Introduces World’s First 2-Nanometer Chip Technology

Visa Collaborates With Wave, Offering Instant Payouts To Canadian Small Business Owners

Walmart Health Enters Agreement To Acquire With Telehealth Provider MeMD

Disney Reports Mixed Second-Quarter Earnings – Disney+ Miss Expectations

McDonald’s Announce Increase In Hourly Wages By 10% For +660 U.S. Owned Restaurants

BIOTECH MAY HAVE FOUND GROUND

The Biotech sector took another hit through Thursday, but rebounded solidly on Friday. The Nasdaq Biotechnology ETF (IBB) closed at $149.68 slightly off from last week’s close of $149.71. The NYSE ARCA Biotech Index (^BTK) closed at 5,564.58 up 29.28 points from last week’s close of 5,535.30. The SPDR S&P Biotech ETF (XBI) closed at $126.92, +3.63% on Friday, but down ~$1 from last Friday’s close of $127.74. The BTK’s 52-wk range is $$97.15-$174.79 and had been getting threes since the early part of March!

Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced this week that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately. In addition, to support the rapid development of the company, Elizabeth Schwarzbach, PhD and Boris Reznik, PhD have joined the Strategic Advisory Board and Elysa Mantel has been appointed as Vice President, General Counsel and Corporate Secretary.

GOLD & SILVER MARKETS TICKED HIGHER

Gold prices closed again above $1800/oz at $1,845, up $11 from the $1,834 close last week. This Friday silver prices closed at $27.52/oz. down $.04 from the $27.56/oz. close last Friday. Hecla Mining (HL) reported impressive Q1 2021 financial and operating results last week and closed at $7.56 up from the $7.27 close last Friday.  See our update story here for greater details.

OIL

Oil prices moved +.7% this week to close at $65.35/bbl and are up +34.7% YTD. It is definitely time may be time to be looking for a Tesla!


PLEASE JOIN ME NEXT TUESDAY!

Did you know ~6.2 million Americans are living with Alzheimer’s disease today & that this number is expected to double over next 30 years?

If yo would like to learn more, then please join me at Tribe Public’s Next FREE Webinar Presentation and Q&A Event titled “Advancing Treatment To Repair Our Aging Innate Immune System to Fight Alzheimer’s” which will be held Tuesday, May 18 (1:15 pm PT/ 4:15 pm ET). The events are efficient  & ~30 minutes in duration.

INMB’s CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss of INmune Bio (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease, will deliver their presentation & will be also be available for a 5-10 minute Q&A session at the end of the presentation.

Register for this FREE event at INMB.TribePublic.com.


TRADING

We are back to 5-trading sessions again next week.


 
VP WATCHLIST UPDATES 
Please review our complete VP Watchlist here that includes a brief list of highlighted companies that includes Apple (AAPL), Disney (DIS), Tesla (TSLA) & a select group of emerging names.  The pages will allow you to learn more and keep up with these companies daily.
Below are updates for five of the emerging companies from the VP Watchlist. 

  • Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed at $14.85pulling back from last week’s $16.26. Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs. 
    • On May 12, Chinook provided a business update and reported financial results for the first quarter ended March 31, 2021. Eric Dobmeier, president and chief executive officer of Chinook Therapeutics stated,  “During the first quarter of 2021, Chinook made strong progress with its pipeline of programs for kidney diseases, including initiating the phase 3 ALIGN and phase 2 AFFINITY trials of atrasentan, presenting encouraging clinical data from the BION-1301 program and entering into a strategic collaboration with Evotec. We are well-capitalized and resourced to execute across our programs to generate additional data catalysts and continue building Chinook into a leading kidney disease company.”

    • On April 15, Chinook’s CEO Eric Dobmeier  & CBO Tom Frohlich delivered a presentation titled “Revolutionizing The Treatment of Kidney Disease” followed by a Q&A session at the Tribe Public Network. You can view the video of the event here. 
  •  
  •  


  • INmune Bio, Inc. (NASDAQ: INMB, $9.78. +5.27%) (52-wk range $4.50-$29.99), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease i.e. Alzheimer’s Disease
    • INmune Bio’s DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is in clinical trial to determine if it can treat for COVID-19 complications (Quellor™), cancer (INB03™), Alzheimer’s and treatment resistant depression (XPro595), and NASH (LIVNate™). The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
    • On May 5th, INMB reported its financial results for the first quarter ended March 31, 2021 and provided a business update on Wednesday, May 5th. RJ Tesi, M.D., chief executive officer of INmune Bio stated, “We continued to treat patients in the Phase I XPro1595 Alzheimer’s disease trial and expand the extensive biomarker data. The interim data that we reported in January confirms that XPro1595 decreases neuroinflammation in patients with Alzheimer’s disease and supports transitioning to a blinded randomized placebo-controlled Phase II trial later this year. We regard these results as extremely promising and look forward to further confirmation of XPro1595’s potential benefit to these patients in a rigorously designed Phase 2 study. We will report the additional biomarker data later this Summer. We have started screening patients in the Phase I INKmune NK cell priming platform trial in patients with high-risk myelodysplastic syndrome (MDS). MDS is a serious hematopoietic stem cell disorder in which patients have functionally defective NK cells, and approximately one-third of cases progress to AML. We created a short 5-minute video that we believe does a wonderful job explaining why NK cells fail to clear cancer and how the cellular and molecular interactions by INKmune activate NK cells to kill resistant tumors. The video can be found by clicking here.
    • I am excited to be hosting Tribe Public’s Next Webinar Presentation and Q&A Event titled “Advancing Treatment To Repair Our Aging Innate Immune System to Fight Alzheimer’s” which will be held Tuesday, May 18 (1:15 pm PT/ 4:15 pm ET). Our events are approximately 30 minutes in duration. INMB’s CEO Dr. Raymond J. Tesi, MD and CFO David J. Moss of INmune Bio (NASDAQ: INMB) will deliver their presentation & will be also be available for a 5-10 minute Q&A session at the end of the presentation. Register for this FREE event at INMB.TribePublic.com.


  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $76.70 & slightly up from last Friday’s close of $76.49. 
    • On May 13th, Fate announced encouraging interim Phase 1 data from the Company’s off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML). The ongoing Phase 1 dose-escalation study of FT516 as monotherapy is currently enrolling patients in the third dose cohort (900 million cells per dose), with three patients treated in the first dose cohort (90 million cells per dose) and six patients treated in the second dose cohort (300 million cells per dose). The Phase 1 dose-escalation study of FT538 as monotherapy is currently ongoing, with three patients treated in the first dose cohort (100 million cells per dose). Learn more. 
    • On May 5th, Fate reported their business highlights and financial results for the first quarter ended March 31, 2021. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “During the first quarter of 2021, we strengthened our balance sheet by raising $460 million and successfully positioned our off-the-shelf, iPSC-derived NK cell pipeline to achieve significant clinical milestones across our disease franchises throughout the remainder of the year. We look forward to sharing Phase 1 clinical data from our FT516 and FT538 programs in relapsed / refractory AML at an investor event to be held alongside the ASGCT conference. We are also pleased with the clinical expansion of our FT538 program into solid tumors, where we plan to combine with FDA-approved monoclonal antibodies targeting EGFR, HER2, and PDL1. While we are disappointed that the PROTECT study of ProTmune did not meet its primary endpoint for prevention of acute graft-versus-host disease following allogeneic stem cell transplant, we will now turn our full attention and resources to our deep pipeline of off-the-shelf, iPSC-derived cancer immunotherapies. We would like to sincerely thank the patients, caregivers and investigators who participated in the clinical investigation of ProTmune, and we intend to share our clinical findings with that community.”

    • In related news, we have made another investment in a private NKcell company called Cytovia Therapeutics, a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies.  Their website is www.cytoviatx.com. This week, Cytovia announced  that Jason Aryeh, a long time biotech investor and board director, has been elected to the Cytovia Board of Directors, effective immediately. In addition, to support the rapid development of the company, Elizabeth Schwarzbach, PhD and Boris Reznik, PhD have joined the Strategic Advisory Board and Elysa Mantel has been appointed as Vice President, General Counsel and Corporate Secretary. Cytovia is seeking to go public in the 2H 2021.


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $2.90, +22.88% Friday and is trading 10.86M shares a day.
    • On May 14, Atossa announced financial results for the fiscal quarter ended March 31, 2021, and provided an update on recent company developments. Dr. Steven Quay, Atossa’s President and Chief Executive Officer stated, “During the first quarter of 2021 we continued our two key development programs, namely our Phase 2 study of oral Endoxifen for the ‘window of opportunity’ between diagnosis of breast cancer and surgery and our Phase 1 study of AT-301 nasal spray for at-home use for patients recently diagnosed with COVID-19. In addition, we continued our ongoing expanded access program with Endoxifen in which the drug continues to be well tolerated and breast cancer recurrence has not been seen clinically. We also received an important authorization from the FDA for an additional expanded access treatment program in an ovarian cancer patient. Combined with very encouraging results in our COVID-19 program with AT-301 nasal spray, we continued to make great progress over the quarter. In the meantime, we leveraged favorable conditions in the capital markets to strengthen our balance sheet over the last few months placing Atossa in a good position to execute on these and potential additional business opportunities during the remainder of 2021. As a result, we are diligently moving our existing programs forward, while actively exploring the possibility for strategic expansion into other areas where we might see near-term milestones and results. We look forward to continuing to update our stockholders on these opportunities as they develop.
  •  
  • Shares of  INVO Bioscience, Inc. (INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, closed at $3.93 up from the close of $3.80/share last Friday. 
    • INVO will report financial results for its first quarter 2021, ended March 31, 2021, after the market close on Monday, May 17, 2021. The Company has scheduled a conference call that same day, Monday, May 17, 2021, at 4:30 pm ET, to review the results. Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751. Live Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company’s website at https://www.invobioscience.com/investors/ or https://www.webcaster4.com/Webcast/Page/2162/40939.

    • INVO announced the appointment of tenured women’s health & fertility solution marketing professional, Meryle Lynn Chamberlain, as Director of Marketing, a newly created position within the company. INVO is focused on an aggressive go-to-market sales, partnerships, and marketing strategy to bring INVOcell, fertility care that is accessible, inclusive, and affordable to the more than 90% of couples in need of fertility treatment that currently go without care.
    • After the close April 26, INVO announced the appointment of Rebecca Messina to the Company’s board of directors. Ms. Messina has broad international experience in leading marketing for elite brands and businesses including Uber Technologies (UBER), Beam Suntory and The Coca-Cola Company (KO). She is currently a Senior Advisor at McKinsey & Company focused on advising internal teams and firm clients in the areas of marketing as a growth lever, including data driven marketing, brand building, and strategically shaping and transforming marketing agendas. Messina has also served as Global Chief Marketing Officer of Uber Technologies (UBER). As Uber’s first-ever CMO, Messina focused on executing Uber’s first global marketing organization, building a world class marketing network, with the mission of helping the company define a strong brand in the hearts and minds of all Uber stakeholders – furthering a movement around the possibilities of “progress for all” in a shared economy. Messina has been the recipient of a number of accolades, including: Forbes World’s Most Influential CMOs, 2019; Ad Age, Women to Watch 2016; Business Insider, Most Innovative CMOs in the World 2016; as well as serving on several boards including the Make-A-Wish Foundation.
    • Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.



  • Shares of NeuBase Therapeutics (NBSE) closed trading this week at $5.08, +9.48% Friday
  •  
    • NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.
    • NBSE reported its financial results for the three- and six-month periods ended March 31, 2021. Dietrich A. Stephan, Ph.D., Founder, CEO and Chairman of NeuBase stated, “We continue to expand and scale our unique precision genetic medicine platform that we believe can turn genes on, off, or edit them in vivo, and thus address most mechanisms that cause diseases in a single industry-unifying solution. Our recent financing led by top-tier healthcare investors enables us to advance our lead program into the clinic next year and expand our pipeline to address historically undruggable oncogenic driver mutations. We look forward to hosting our R&D day on June 8th, during which we will present an update on our current pipeline programs, as well as introduce an oncology program targeting a genetic driver mutation in a high value indication.”


Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates. 

Investing & Inspiration

  1. “Cash – in savings accounts, short-term CDs or money market deposits – is great for an emergency fund. But to fulfill a long-term investment goal like funding your retirement, consider buying stocks. The more distant your financial target, the longer inflation will gnaw at the purchasing power of your money.”  – Suze Orman
  2. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  3. “I think you have to learn that there’s a company behind every stock and there’s only one real reason why stocks go up. Companies go from doing poorly to doing well or small companies grow to large companies.” – Peter Lynch
  4. “Historically, there has been a bull market in the commodities every 20 or 30 years.” – Jim Rogers
  5. “The markets generally are unpredictable, so that one has to have different scenarios. The idea that you can actually predict what’s going to happen contradicts my way of looking at the market.” – George Soros
  6. “Stop trying to predict the direction of the stock market, the economy or the elections.” – Warren Buffett
  7. “An important key to investing is to remember that stocks are not lottery tickets.” – Peter Lynch
  8. “Learn everyday, but especially from the experiences of others. It’s cheaper!” – John Bogle
  9. “When purchasing depressed stock in troubled companies, seek out the ones with the superior financial positions and avoid the ones with loads of bank debt.” – Peter Lynch
  10. “No stock price is too low for bears or too high for bulls.” –  John F. Heerdink, Jr.
  11. “Investment is most successful when it is most businesslike.” – Ben Graham
  12. “Value stocks are about as exciting as watching grass grow, but have you ever noticed just how much your grass grows in a week?” – Christopher Browne
  13. “Even the intelligent investor is likely to need considerable willpower to keep from following the crowd.” – Benjamin Graham
  14. “Individual who cannot master their emotions are ill-suited to profit from the investment process.” – Benjamin Graham
  15. “I made my first investment at age eleven. I was wasting my life until then.” – Warren Buffet
  16. “I don’t look to jump over seven-foot bars; I look around for one-foot bars that I can step over.” — Warren Buffett
  17. “There are only three measurements that tell you nearly everything you need to know about your organization’s overall performance: employee engagement, customer satisfaction, and cash flow. It goes without saying that no company, small or large, can win over the long run without energized employees who believe in the mission and understand how to achieve it.” – Jack Welch, former CEO of GE
  18. “Opportunities come infrequently. When it rains gold, put out the bucket, not the thimble” ― Warren Buffett
  19. “If you buy things you do not need, soon you will have to sell things you need.” – Warren Buffet
  20. “How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen
  21. “It’s far better to buy a wonderful company at a fair price, than a fair company at a wonderful price.” – Warren Buffett
  22. “A market downturn doesn’t bother us. It is an opportunity to increase our ownership of great companies with great management at good prices.” — Warren Buffett
  23. “Every once in a while, the market does something so stupid it takes your breath away.” — Jim Cramer
  24. “The person who starts simply with the idea of getting rich won’t succeed; you must have a larger ambition.” — John D. Rockefeller
  25. “Know what you own, and know why you own it.” – Peter Lynch
  26. “Although it’s easy to forget sometimes, a share is not a lottery ticket… it’s part ownership of a business.” – Peter Lynch
  27. “Wise spending is part of wise investing. And it’s never too late to start.” – Rhonda Katz

  28. “Invest for the long haul. Don’t get too greedy and don’t get too scared.” – Shelby M.C. Davis

  29. “Fear incites human action far more urgently than does the impressive weight of historical evidence.”
    -Jeremy Siegel

  30. With a good perspective on history, we can have a better understanding of the past and present, and thus a clear vision of the future.” — Carlos Slim Helu
  31. “If we like a business, we’re going to buy as much of it as we can and keep it as long as we can. And when we change our mind, we don’t take half measures.” – Warren Buffett
  32. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  33. “Never depend on a single income, make an investment to create a second source.” Warren Buffet“Games are won by players who focus on the playing field –- not by those whose eyes are glued to the scoreboard.” ― Warren Buffett
  34. “The key to making money in stocks is not to get scared out of them.” – Peter Lynch
  35. “Courage taught me no matter how bad a crisis gets … any sound investment will eventually pay off.” — Carlos Slim Helu
  36. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  37. “As time goes on, I get more and more convinced that the right method of investment is to put fairly large sums into enterprises which one thinks one knows something about and in the management of which one thoroughly believes.” — John Maynard Keynes
  38. “Given a 10% chance of a 100 times payoff, you should take that bet every time.” — Jeff Bezos
  39. “Money is always eager and ready to work for anyone who is ready to employ it.” ― Idowu Koyenikan
  40. “The secret to investing is to figure out the value of something – and then pay a lot less.” – Joel Greenblatt
  41. “We don’t have an analytical advantage, we just look in the right place.” – Seth Klarman
  42. “Men, it has been well said, think in herds. It will be seen that they go mad in herds, while they only recover their senses slowly, and one by one.” – Charles Mackay
  43. “It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
  44. “In investing, what is comfortable is rarely profitable.” — Robert Arnott
  45. “Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
  46. “No Price is too low for a bear or too high for a bull.” — Anonymous
  47. “Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
  48. “Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
  49. “Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
  50. “If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
  51. “It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
  52. “A bull market is like sex. It feels best just before it ends.” — Barton Biggs
  53. “The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
  54. “No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
  55. “The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
  56. “Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
  57. “Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
  58. “The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
  59. “Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
  60. “Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
  61. “Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
  62. “You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr. 
  63. “We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
  64. “Never test the depth of the river with both of your feet.” – Warren Buffet
  65. “Know what you own, and know why you own it.” – Peter Lynch
  66. “Liquidity is only there when you don’t need it.” -Old Proverb
  67. “There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
  68. “If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
  69. Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
  70. “In investing, what is comfortable is rarely profitable.” – Robert Arnott
  71. “Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
  72. “The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
  73. “The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
  74. “It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
  75. “Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
  76. “Remember that the stock market is a manic depressive.”  – Warren Buffett
  77. “An investment in knowledge pays the best interest.” – Benjamin Franklin
  78. “I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
  79. “Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
  80. “The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
  81. “If all the economists were laid end to end, they’d never reach a conclusion.
    -George Bernard Shaw
  82. “The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
  83. “In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
  84. “In investing, what is comfortable is rarely profitable.” -Robert Arnott
  85. “The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
  86. “How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
  87. “Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
  88. Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
  89. “The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
  90. “I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
  91. “Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers

Videos

Please consider viewing these interesting videos: